Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEM-ST
- Development stage
- Unknown
- Lead developer
- Lamark
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PEM-ST is a clinical-stage therapeutic candidate developed by Lamark for the treatment of lung cancer. It is a modified version of the anti-PD-1 monoclonal antibody pembrolizumab, utilizing Lamark's proprietary "Soft-Targeting" (ST) technology. The ST platform is designed to optimize the pharmacokinetic profile and tissue distribution of established biologics, potentially enhancing their therapeutic index by improving tumor penetration or reducing systemic immune-related adverse events. By binding to the programmed cell death protein 1 (PD-1) receptor, PEM-ST blocks the inhibitory signals from PD-L1 and PD-L2, thereby restoring and enhancing T-cell mediated anti-tumor immune responses. The drug is currently being evaluated in Phase 1/2 clinical trials.
- Other names
- pembrolizumab-ST
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PEM-ST.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEM-ST.